CSI Market
Sign In | Register

Ngm Biopharmaceuticals Inc (NGM) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NGM Annual Cash Flow →
Reviewing cash flow figures over time highlights how Ngm Biopharmaceuticals Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2023)
12 Months 		(Sep 30 2023) (Jun 30 2023) (Mar 31 2023) (Dec 31 2022)
Operating Activities
Income-142.38
Depreciation & amortization2.22
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation28.72
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Increase Decrease In Due From Related Parties Contract Assets Noncash-
Operating Lease Right Of Use Asset Amortization Expense1.56
Increase Decrease In Contract With Customer Asset-
Increase Decrease In Operating Lease Liability-4.00
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable, Related Parties7.52
Increase (Decrease) in Accounts Payable-4.98
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-16.97
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.65
Other Working Capital0.15
Other Noncash Income (Expense)1.07
Other net0.00
Payments for (Proceeds from) Other Operating Activities-5.92
Discontinued operations0.00
Net Cash flow from Operating Activities-132.20
Investing Activities
Capital Expenditures-1.25
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities220.97
Payments to Acquire Marketable Securities-105.43
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities114.29
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.78
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-77.41
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents77.41
Restricted Cash Noncurrent-
Proceeds From Issuance Open Market Agreement-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.78
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-133.45
Total Cash Flow-16.14
4 historic quarters locked

Sign in to unlock the full Ngm Biopharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Ngm Biopharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20231231)
  • Filed with the SEC: March 11, 2024
  • Source: ngm-20231231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-24-010232

Figures are derived from filed reports and may be restated. Historical data is subject to revision.